Adoption of Multi-class Fixed Dose Combination Once-daily Single Tablet HIV Regimen in Europe

¹SVP and Global Head, Global Evidence, Value and Access, Ipsos Healthcare, Washington, USA.

Corresponding Author: Narayanan S, SVP and Global Head, Global Evidence, Value and Access, Ipsos Healthcare, 2020 K Street NW, Suite 410, Washington, DC, 20006, USA. Tel: +1 203-297-1208; E-Mail: [email protected]

Received Date: 03 May 2016  
Accepted Date: 27 May 2016   
Published Date: 03 Jun 2016

Copyright © 2016 Narayanan S

Citation: Narayanan S. (2016). Adoption of Multi-class Fi xed Dose Combination Once-daily Single Tablet HIV Regimen in Europe.Mathews J HIV AIDS. 1(1): 005.

ABSTRACT

Background and Aims

Once-daily multi-class fixed dose combination (FDC) once-daily single tablet regimen (STR) is critical part of antiretroviral treatment armamentarium to manage patients with human immunodeficiency virus (HIV). Multi-wave retrospective medical chart reviews of HIV patients were conducted in Europe (5EU: UK/France/Germany/Italy/Spain) between 1Q2009 and 1Q2015 among patients initiating or switching HIV regimen. Over 1Q2009-1Q2015, 200 physicians abstracted an average of 3000 patient charts per quarter. STR prescribing trends increased in 5EU over the years: 1Q2009- 17%, 1Q2010/1Q2011-23%, 1Q2012-24%, 1Q2013-30%, 1Q2014-44%, 1Q2015-53%. The top reasons for switching from conventional antiretroviral regimen dosing to an STR in 1Q2009/1Q2015 were simplification (74%/64%), tolerability (14%/19%), and patient decision (12%/18%). These observed trends may emphasize the importance HIV providers have given towards maintaining HIV patients on a simple and yet tolerable regimen with the hope to achieve optimal adherence and clinical outcomes over the longer term.

KEYWORDS

HIV; Single Tablet Regimen; STR, Fixed Dose Combination; FDC, Europe.